The invention relates to a flat gas discharge lamp having a discharge vessel and electrodes, the discharge vessel comprising a base plate (1) and a top plate (7) and having at least one spacer element (8) between base plate (1) and top plate (7). Spacer elements usually disrupt the homogeneity of th
The invention relates to a flat gas discharge lamp having a discharge vessel and electrodes, the discharge vessel comprising a base plate (1) and a top plate (7) and having at least one spacer element (8) between base plate (1) and top plate (7). Spacer elements usually disrupt the homogeneity of the luminance distribution on the top plate 7. In order to avoid this, the spacer elements (8) are additionally configured as dielectrically impeded electrodes. For this purpose, each spacer element (8) has an electrically conductive component (9) connected to an electrode or current feed. As a result, the spacer elements (8) are actively involved in the discharge and, consequently, in the production of light.
대표청구항▼
The invention relates to a flat gas discharge lamp having a discharge vessel and electrodes, the discharge vessel comprising a base plate (1) and a top plate (7) and having at least one spacer element (8) between base plate (1) and top plate (7). Spacer elements usually disrupt the homogeneity of th
The invention relates to a flat gas discharge lamp having a discharge vessel and electrodes, the discharge vessel comprising a base plate (1) and a top plate (7) and having at least one spacer element (8) between base plate (1) and top plate (7). Spacer elements usually disrupt the homogeneity of the luminance distribution on the top plate 7. In order to avoid this, the spacer elements (8) are additionally configured as dielectrically impeded electrodes. For this purpose, each spacer element (8) has an electrically conductive component (9) connected to an electrode or current feed. As a result, the spacer elements (8) are actively involved in the discharge and, consequently, in the production of light. e anthracycline is administered between 20 and 120 days before or after the 20(S)-caamptothecin is administered and is also administered within 20 days of when the 20(S)-camptothecin is administered. 19. A method according to claim 1 wherein the anthracycline is administered between 30 and 120 days before or after the 20(S)-camptothecin is administered and is also administered within 30 days of when the 20(S)-camptothecin is administered. 20. A method according to claim 1 wherein the anthracycline is administered between 40 and 120 days before or after the 20(S)-camptothecin is administered and is also administered within 40 days of when the 20(S)-camptothecin is administered. 21. A method according to claim 1 wherein the anthracycline is selected from the group consisting of: doxorubicin, duanorubicin, idarubicin, epirubicin, and mitoxantrone and aclacinomycin A. 22. A method according to claim 1 wherein the anthracycline is doxorubicin. 23. A method according to claim 1 wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin. 24. A method according to claim 1 wherein the disease associated with undesirable or uncontrolled cell proliferation is cancer. 25. A method according to claim 1 wherein the cancer is selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and stomach cancer. 26. A method according to claim 1 wherein the disease associated with undesirable or uncontrolled cell proliferation is pancreatic cancer. 27. A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not present in a pharmacologically active form in patient's blood, and administering a 20(S)-camptothecin to the patient. 28. A method according to claim 27 wherein the anthracycline is administered at least 10 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 29. A method according to claim 27 wherein the anthracycline is administered at least 20 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 30. A method according to claim 27 wherein the anthracycline is administered at least 30 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 31. A method according to claim 27 wherein the anthracycline is administered at least 40 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 32. A method according to claim 27 wherein the anthracycline is administered at least 50 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 33. A method according to claim 27 wherein the anthracycline is administered between 10 and 120 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 34. A method according to claim 27 wherein the anthracycline is administered between 20 and 120 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 35. A method according to claim 27 wherein the anthracycline is administered between 30 and 120 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 36. A method according to claim 27 wherein the anthracycline is administered between 40 and 120 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 37. A method according to claim 27 wherein the anthracycline is administered between 50 and 120 days before the 20(S)-camptothecin is present in a pharmacologically active form in patient's body. 38. A method according to claim 27 wherein the
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (9)
Martin Paul C. (Vancouver WA) Buzak Thomas S. (Aloha OR), Bi-channel electrode configuration for an addressing structure using an ionizable gaseous medium and method of operating.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.